Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22


(18)F-FET-PET in Primary Hyperparathyroidism: A Pilot Study.

Krakauer M, Kjaer A, Bennedbæk FN.

Diagnostics (Basel). 2016 Aug 17;6(3). pii: E30. doi: 10.3390/diagnostics6030030.


Usefulness of positron emission tomographic studies for gliomas.

Miyake K, Ogawa D, Okada M, Hatakeyama T, Tamiya T.

Neurol Med Chir (Tokyo). 2016 Jul 15;56(7):396-408. doi: 10.2176/nmc.ra.2015-0305. Epub 2016 May 31.


New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.

Mesguich C, Zanotti-Fregonara P, Hindié E.

Theranostics. 2016 Jan 1;6(2):287-90. doi: 10.7150/thno.14400. eCollection 2016.


11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.

Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jörg G, Samnick S, Herrmann K, Buck AK, Einsele H, Lückerath K.

Theranostics. 2016 Jan 1;6(2):254-61. doi: 10.7150/thno.13921. eCollection 2016.


Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma.

Yoo MY, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE, Kang KW.

Nucl Med Mol Imaging. 2015 Dec;49(4):291-7. doi: 10.1007/s13139-015-0362-0. Epub 2015 Aug 29.


11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.

Lückerath K, Lapa C, Albert C, Herrmann K, Jörg G, Samnick S, Einsele H, Knop S, Buck AK.

Oncotarget. 2015 Apr 10;6(10):8418-29.


Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.

Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Oyama T, Asao T, Matsumoto M, Sawamura M.

Cancer Sci. 2014 Nov;105(11):1496-502. doi: 10.1111/cas.12529. Epub 2014 Oct 9.


Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.

Takahashi Y, Akahane T, Yamamoto D, Nakamura H, Sawa H, Nitta K, Ide W, Hashimoto I, Kamada H.

Mol Clin Oncol. 2014 Jul;2(4):525-529. Epub 2014 May 5.


Systemic Endoradiotherapy with Carrier-Added 4-[(131)I]Iodo-L-Phenylalanine: Clinical Proof-of-Principle in Refractory Glioma.

Baum RP, Kluge A, Gildehaus FJ, Bronzel M, Schmidt K, Schuchardt C, Senftleben S, Samnick S.

Nucl Med Mol Imaging. 2011 Dec;45(4):299-307. doi: 10.1007/s13139-011-0116-6. Epub 2011 Nov 16.


PET/CT in Oncology: Current Status and Perspectives.

Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K.

Curr Radiol Rep. 2013 May 3;1:177-190. eCollection 2013.


Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.

Juhász C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00015. Review.


Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.

Kamson DO, Mittal S, Robinette NL, Muzik O, Kupsky WJ, Barger GR, Juhász C.

Neuro Oncol. 2014 Oct;16(10):1373-83. doi: 10.1093/neuonc/nou042. Epub 2014 Mar 26.


Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology.

Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK.

PLoS One. 2013 Dec 23;8(12):e84840. doi: 10.1371/journal.pone.0084840. eCollection 2013.


Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis.

Shishido H, Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T.

Cancers (Basel). 2012 Mar 1;4(1):244-56. doi: 10.3390/cancers4010244.


Evaluation of the biodistribution of 11C-methionine in children and young adults.

Harris SM, Davis JC, Snyder SE, Butch ER, Vavere AL, Kocak M, Shulkin BL.

J Nucl Med. 2013 Nov;54(11):1902-8. doi: 10.2967/jnumed.112.118125. Epub 2013 Sep 19.


Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.

Kamson DO, Juhász C, Buth A, Kupsky WJ, Barger GR, Chakraborty PK, Muzik O, Mittal S.

J Neurooncol. 2013 Mar;112(1):121-32. doi: 10.1007/s11060-013-1043-4. Epub 2013 Jan 9.


The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.

Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, Giannini C, Laack NN, Parney IF, Lowe VJ, Brinkmann DH, Sarkaria JN.

J Neurooncol. 2013 Jan;111(1):11-8. doi: 10.1007/s11060-012-0986-1. Epub 2012 Oct 20.


Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET.

Alkonyi B, Barger GR, Mittal S, Muzik O, Chugani DC, Bahl G, Robinette NL, Kupsky WJ, Chakraborty PK, Juhász C.

J Nucl Med. 2012 Jul;53(7):1058-64. doi: 10.2967/jnumed.111.097881. Epub 2012 May 31.


Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas.

Miyake K, Shinomiya A, Okada M, Hatakeyama T, Kawai N, Tamiya T.

J Biomed Biotechnol. 2012;2012:205818. doi: 10.1155/2012/205818. Epub 2012 Apr 11.


Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas.

Haining Z, Kawai N, Miyake K, Okada M, Okubo S, Zhang X, Fei Z, Tamiya T.

BMC Clin Pathol. 2012 Feb 28;12:4. doi: 10.1186/1472-6890-12-4.

Items per page

Supplemental Content

Support Center